Glivec: The patently David vs Goliath battle
Our battle had started when Novartis got exclusive marketing rights (EMR) on Imatinib (2003). The impact was immediate: Six of nine generic producers stopped supply. We went to the Supreme Court in 2004 to overturn the EMR. Before the case was heard, the new patent law came into force and …